Waypoint Bio Raises $14.5M in Seed Funding

Waypoint Bio, a biotechnology company based in New York City that specializes in novel cell therapies for solid tumors, has raised $14.5 million in seed funding.

The funding round was led by Hummingbird Ventures, with participation from Recode Ventures and pre-seed lead Fifty Years. Waypoint Bio plans to use the funds to advance its CAR T-cell therapies targeting the tumor microenvironment and to develop Treg therapies for autoimmune diseases.

Waypoint Bio was co-founded by CEO Xinchen Wang and CSO David Phizicky. The company leverages proprietary spatial pooled screening technology and a lab-in-the-loop approach to advance novel cell therapies for solid tumors. While its primary focus is on developing innovative cancer treatments, the company’s technology also supports drug discovery for applications such as Treg therapies for autoimmune diseases.

The co-founders lead a team of 11 researchers, scientists, and engineers, and are supported by a diverse, expert Scientific Advisory Board.

© TechMub. All right reserved.

Source link